Scarica l'app Stockscreener
8.3785
0.85%
-0.0715
Dopo l'orario di chiusura:
8.36
-0.0185
-0.22%
Precedente Chiudi:
$8.45
Aprire:
$8.494
Volume 24 ore:
15,100
Relative Volume:
0.28
Capitalizzazione di mercato:
$590.86M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-7.21%
1M Prestazione:
-22.13%
6M Prestazione:
-46.21%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$8.17
$8.494
Intervallo di 1 settimana:
$8.17
$9.459
Portata 52W:
$7.90
$25.00
Yd Bio Ltd Stock (YDES) Company Profile
Compare YDES vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
YDES
Yd Bio Ltd
|
8.3785 | 595.91M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Yd Bio Ltd Borsa (YDES) Ultime notizie
YD Bio Forms Taiwan-U.S. Dual-Core FDA Regulatory Platform in Alliance with YC Biotech - TipRanks
YD Bio (Nasdaq: YDES) builds Taiwan-U.S. FDA regulatory platform - Stock Titan
YD Bio partners with YC Biotech to establish Taiwan-US dual-core regulatory platform - BioSpectrum Asia
YD Bio Says US Unit Selected as FDA Liaison for YC Biotech's Asia Clients - marketscreener.com
Yd Bio Limited announces strategic partnership with Yc Biotech Co - marketscreener.com
SunPower to Participate in the 38th Annual ROTH Conference - The Manila Times
Rumble App Now Includes Rumble Shorts on iPhones Following Apple Approval - The Manila Times
The Chefs’ Warehouse, Inc. to Participate in the UBS Global Consumer & Retail Conference - The Manila Times
Freshworks to Participate in Upcoming Investor Conferences - The Manila Times
The Oncology Institute to Participate in Multiple Healthcare Investor Conferences in March - The Manila Times
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - The Manila Times
Prime Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Major Shareholder Announcement - The Manila Times
YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform - marketscreener.com
Inside YD Bio’s new Taiwan‑U.S. gateway for FDA drug and device approvals - Stock Titan
Ethan Shen holds 77.06% of YD Bio Ltd (YDES) as amended ownership filing - Stock Titan
YD Bio Ltd (YDES) PE Ratio (TTM) Chart - GuruFocus
YD Bio Shares Spark Retail Trader Buzz Following Nasdaq Debut via Breeze SPAC - MSN
CMB.TECH to Release Q4 2025 Earnings on February 26, 2026 - Intellectia AI
CMB.TECH Sells Two VLCCs, Realizing $98.2 Million Gain - Intellectia AI
Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE - RTTNews
YD Bio Signs Binding LOI to Acquire Taiwan Immunotherapy Firm SSMC - TipRanks
YD Bio to acquire Taiwan’s SSMC for $26.87 million By Investing.com - Investing.com Nigeria
YD Bio to acquire Taiwan’s Safe Save Medical in $26.9 million deal By Investing.com - Investing.com South Africa
YD Bio to acquire Taiwan’s Safe Save Medical in $26.9 million deal - Investing.com Canada
YD Bio Signs LOI To Acquire Safe Save Medical, Expanding Immunocell Therapy Leadership - Nasdaq
YD Bio enters into binding LOI to acquire shares, assets of SSMC - TipRanks
YD Bio to acquire Taiwan’s SSMC for $26.87 million - Investing.com
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy - The Manila Times
Cancer detection firm YD Bio targets $26.87M glioblastoma cell therapy deal - stocktitan.net
Diabetic Macular Edema Pipeline 2025: Comprehensive Clinical Trials and Therapies Analysis with Key MOA and ROA Insights by DelveInsight | Oxurion, Ocuphire Pharma, YD Life Science, Unity Biotech - Barchart.com
YD Bio Limited Announces Directorate Changes - marketscreener.com
YDES Stock Price, News & Analysis - Stock Titan
YD Bio Limited (YDES) board reshaped by majority holders’ written consent - Stock Titan
YD Biopharma is an integrated biotechnology company that is poised to have a transformational year as it expands business operations. - Research Tree
YD Bio enters MOU to merge with EG BioMed in cancer diagnostics deal - Investing.com Australia
YD Bio enters MOU to merge with EG BioMed in cancer diagnostics deal By Investing.com - Investing.com South Africa
How an AI cancer test in Taipei hospitals could help shape future drugs - Stock Titan
YD Bio Limited entered into a Memorandum of Understanding to acquire EG BioMed Co., Ltd. - MarketScreener
YD Bio advances cancer detection and eye disease platforms By Investing.com - Investing.com Australia
YD Bio LtdPlans to evaluate up to three acquisitions in 2026 - marketscreener.com
Yd Bio LtdPlans To Evaluate Up To Three Acquisitions In 2026 - TradingView — Track All Markets
YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap - Yahoo Finance
Micron and Lam Research among market cap stock movers on Tuesday By Investing.com - Investing.com India
YD Bio Limited Warrants (YDESW) Competitors - Meyka
YD Bio (YDES) Stock Price, News & Analysis - MarketBeat
YD Bio to establish California operations center for diagnostic development By Investing.com - Investing.com Australia
YD Bio to establish California operations center for diagnostic development - Investing.com India
YD Bio (Nasdaq: YDES) plans Calif. ops center for U.S. diagnostics - Stock Titan
Assessing YD Bio (YDES) Valuation After a Sharp One-Month Share Price Rebound - simplywall.st
YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN - Finviz
Yd Bio Ltd Azioni (YDES) Dati Finanziari
Non sono disponibili dati finanziari per Yd Bio Ltd (YDES). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):